Stockreport

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformation...

Protara Therapeutics, Inc.  (TARA) 
PDF 80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with o [Read more]